Correction, October 24, 2026: An earlier version of this article said no medical device is FDA-authorized for stimulant use disorder. reSET, a prescription digital therapy, received FDA De Novo authorization in 2017 for substance use disorder in patients not primarily using opioids, which includes stimulant use. The earlier version also omitted a 2025 sham-controlled follow-up, co-authored by NET Recovery’s chief executive, in which active and sham groups reported similar post-discharge stimulant use. The headline, summary and article have been revised.
No medication is FDA-approved to treat cocaine or methamphetamine use disorder. The one FDA-authorized device that reaches it is reSET, a prescription digital therapy granted De Novo authorization in 2017 as an adjunct to outpatient treatment for substance use disorder broadly. NET Recovery is now trying to add a device already on the market for something else. The FDA granted the company’s NET Device Breakthrough Device Designation September 23 for reducing psychostimulant use in adults with stimulant use disorder, a designation that speeds up the agency’s review process without establishing that the device works for this use. The evidence NET Recovery has published so far for the new indication is not the kind of evidence that got the device cleared for its current one.
What the device is already cleared for
The NET Device, a battery-powered transcutaneous alternating current stimulator worn at both ears, received FDA 510(k) clearance in May 2024 for managing opioid withdrawal symptoms in patients with opioid use disorder, alongside standard medications and other withdrawal therapies. That clearance rested on a prospective, randomized, sham-controlled trial of 108 adults at a single US site, according to the FDA’s own published summary of the submission. Average withdrawal severity, measured on the Clinical Opiate Withdrawal Scale, fell 61 percent in the active-device group and 46 percent in the sham group one hour after treatment began, a gap the FDA’s summary reports as 15 percentage points with a plus-or-minus 10 percentage point interval. A larger share of the active group, 98 percent versus 84 percent, reached the trial’s predefined threshold for a clinically meaningful reduction. The submission also reported that blinding was not fully maintained: participants assigned to the active device were more likely to correctly identify their assignment than participants assigned to sham, though the specific test for that difference did not cross the conventional threshold for statistical significance. Active and sham stimulation can feel different without erasing the value of a control group, but it is a limitation the agency’s own summary records, not one the trial escaped.
What supports the new indication
Stimulant use disorder is a different claim, on a different evidentiary footing. NET Recovery has not published a sham-controlled trial in stimulant use disorder. The nearest controlled evidence comes from its opioid research: a 2025 follow-up in Frontiers in Psychiatry of 103 participants from a randomized trial of the active device against sham during residential opioid discontinuation (NCT04916600), half of whom also used stimulants. Over 12 weeks after discharge, active and sham groups reported similar rates of stimulant use. A planned secondary analysis found fewer stimulant-use days among participants who used the active device for more than 24 hours, a finding its authors, who include NET Recovery’s chief executive, say needs to be replicated.
The other public evidence is a real-world data analysis of 221 adults using the device in residential addiction treatment and detention settings, roughly half with stimulant use alone and half with combined stimulant and opioid use, accepted for publication in Frontiers in Psychiatry in August 2026. It tracked withdrawal severity on the Amphetamine Cessation Symptom Assessment scale and reported substantial reductions within an hour, continuing over several days, in both groups. The study measured withdrawal symptoms, not whether participants subsequently reduced stimulant use. Its findings therefore do not establish the outcome NET Recovery is seeking authorization to claim. It had no control arm, and its own authors recommend a sham-controlled randomized trial as the logical next step, the same design already completed for the opioid indication but not yet run for this one. NET Recovery has not stated whether this study was part of what it submitted to support the breakthrough application; the company’s release does not name the supporting evidence.
What the designation does and does not do
Breakthrough Device Designation is a process benefit, not a finding about the device. It gives NET Recovery more frequent interaction with FDA staff and priority review of a future submission. FDA’s own program criteria require two things together: a reasonable expectation, based on preliminary clinical evidence, that the device provides more effective treatment or diagnosis of a life-threatening or irreversibly debilitating condition, and at least one of four additional criteria, which can include the absence of an approved or cleared alternative. That preliminary, reasonable-expectation standard is a materially lower evidentiary bar than what FDA requires to authorize a device for marketing; designation is not a finding that the device works, but it is not evidence-free either. NET Recovery’s release says no drug or device is approved or cleared for stimulant use disorder, without stating which specific criterion FDA applied in granting the designation. reSET’s 2017 authorization was a De Novo grant, not a clearance, and it covers substance use disorder broadly rather than stimulant use disorder by name. NET Recovery’s own release is explicit that the designation “does not change FDA clearance or approval requirements” and that the device “is not currently authorized for the treatment of stimulant use disorder,” calling that use investigational. The company says it is designing a pivotal randomized controlled trial it expects to pursue through the FDA’s De Novo pathway, used when a device has no existing predicate for its claimed indication. No protocol has been registered publicly, and the company has not disclosed a trial size, timeline, or whether it will include a sham arm.
Why the gap still matters
The absence of an FDA-approved medication for stimulant use disorder is not company framing. Cocaine and methamphetamine addiction have no FDA-approved pharmacotherapy, unlike opioid use disorder, which has three. On devices, the picture is narrower than the company’s framing: reSET is authorized for substance use disorder, including stimulant use, when patients are not primarily using opioids, though it is software delivering behavioral therapy, not a neurostimulator. That gap is specific to FDA-regulated products: contingency management, a behavioral therapy that rewards verified abstinence with small incentives, is a well-established, evidence-based treatment for stimulant use disorder, according to the National Institute on Drug Abuse, and sits outside what any FDA clearance or approval process governs. Stimulant-involved deaths made up 59 percent of US overdose deaths from January 2021 through June 2024, according to the CDC’s own published surveillance data, with 43 percentage points of that share involving stimulants together with opioids and the remainder involving stimulants without opioids. A device that does not depend on a pharmacological target, if it eventually clears a controlled trial, would enter a market with no approved medication to displace, alongside an established behavioral standard of care and one authorized digital therapy. That is what makes the designation worth tracking despite what it does not yet prove: it marks where regulators are willing to move quickly, not where the evidence currently stands.
What to watch
Whether NET Recovery’s planned pivotal randomized trial for stimulant use disorder includes a sham comparator, as the real-world study’s authors recommend, and what population and primary endpoint it specifies. Whether the company discloses what evidence it submitted to support the breakthrough application. And when NET Recovery registers the trial’s protocol, which would be the first public confirmation of its design.